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Abstract
Background: Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal tumors to develop in the
digestive tract. These tumors are highly resistant to conventional chemotherapy and only the introduction of
imatinib mesylate has improved the prognosis of patients. However, Response Evaluation Criteria in Solid Tumors
are inappropriate for assessing tumor response, and the histological/pathological response to imatinib is variable,
heterogeneous, and does not associate with clinical response. The effects of imatinib on responding GISTs are still
being explored, and few studies correlate the clinical response with the histological response after pharmacological
treatment. Recently, apoptosis and autophagy were suggested as possible alternative mechanisms of
pharmacological response.
Methods: Here, we used a proteomic approach, combined with other analyses, to identify some molecular stromal
components related to the response/behavior of resected, high-risk GISTs after neoadiuvant imatinib therapy.
Results: Our proteomic results indicate an elevated concentration of Stem Cell Growth Factor (SCGF), a
hematopoietic growth factor having a role in the development of erythroid and myeloid progenitors, in imatinib-
responsive tumor areas. SCGFa expression was detected by mass spectrometry, immunohistochemistry and/or
western blot and attributed to acellular matrix of areas scored negative for KIT (CD117). RT-PCR results indicated
that GIST samples did not express SCGF transcripts. The recently reported demonstration by Gundacker et al. [1] of
the secretion of SCGF in mature pro-inflammatory dendritic cells would indicate a potential importance of SCGF in
tissue inflammatory response. Accordingly, inflammatory infiltrates were detected in imatinib-affected areas and the
CD68-positivity of the SCGF-positive and KIT-negative areas suggested previous infiltration of monocytes/
macrophages into these regions. Thus, chronic inflammation subsequent to imatinib treatment may determine
monocyte/macrophage recruitment in imatinib-damaged areas; these areas also feature prominent tumor-cell loss
that is replaced by dense hyalinization and fibrosis.
Conclusions: Our studies highlight a possible role of SCGFa in imatinib-induced changes of GIST structure,
consistent with a therapeutic response.
Background
Gastrointestinal stromal tumors (GISTs) are the most
frequent mesenchymal tumors to develop in the digestive
tract. They typically arise from the stomach (40-70%) or
small intestine (20-40%) but can also occur in the colon-
rectum (10-15%) and rarely in the esophagus. At least
10-30% of tumors are discovered incidentally during
laparotomy, endoscopy, or other imaging studies; 15-47%
of patients present with overt metastatic disease and
common sites of metastases include liver, peritoneum,
and omentum [2-4]. GISTs are thought to originate from
the interstitial cells of Cajal or their precursor cells [5].
Most GISTs are characterized by gain-of-function muta-
t i o n si nt h eg e n e se n c o d i n gKIT and platelet-derived
growth factor receptor alpha (PDGFRA)[ 6 ] ,m u t a t i o n s
that appear to be mutually exclusive. The emerging role
of stem cell factor (SCF) as the ligand of the receptor
tyrosine kinase KIT [7-9] suggests that an autocrine-
paracrine loop serves as a possible further mechanism of
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important role not only in the differentiation and prolif-
eration of interstitial cells of Cajal and the development
of GISTs but also in the development of hematopoietic
cells such as mast cells, erythroblasts, and melanocytes
[11].
GISTs are highly resistant to conventional chemother-
apy [12]; in the past decade, the introduction of imatinib
mesylate (Gleevec
®, Novartis Pharmaceutical Corporation,
NJ, USA), a KIT receptor blocker, has significantly
improved the prognosis of GIST patients. Tumor response
depends on the presence/absence and type of mutations in
KIT or PDGFR. Unfortunately, the major problem with
imatinib treatment is resistance, mainly secondary resis-
tance that generally evolves in most patients after a med-
ian of two years of therapy [13,14].
Eighty to eighty-five percent of patients with advanced
GISTs exhibit an initial benefit from imatinib treatment;
however, the response level varies from rapid and gross
reduction in tumor volume to little or no tumor shrink-
age (described as stable disease) [6]. Size-based response
criteria such as the World Health Organization criteria
or the current international Response Evaluation Criteria
in Solid Tumors are thus thought to underestimate the
response and are not appropriate tools to assess tumor
response to imatinib [15]. Consequently, the clinical
management of these patients and the criteria used to
assess clinical response to imatinib therapy have recently
been redefined [16]. In accordance with previously
reported criteria, GISTs can be classified using the fol-
lowing scores: high responders, 0 to <50% residual viable
tumor cells with no mitosis, and no obvious Ki-67 immu-
nostaining; moderate responders, >50% to 90% tumor
cells, no mitosis, and Ki-67 immunostaining in 0 to <10%
of cells; low responders, >50% to 90% tumor cells, mitotic
index > 10/50 high-power fields, Ki-67 immunostaining
in 20-30% or >30% of cells; and non-responders, >90%
tumor cells [17,18].
The histological/pathological response of GIST to imati-
nib therapy is also variable and heterogeneous from
nodule to nodule within the same resection, as well as
within the same lesion, and does not correlate well with
clinical response. Limited studies of the histopathological
changes in imatinib-treated patients indicate a significant
change in the appearance of the tumor tissue following
preoperative systemic imatinib therapy in GISTs; altera-
tions particularly occur in the stromal compartment and
are visible during standard pathological assessment. The
density of the tumor and the number of intratumoral
vessels decrease significantly and areas of cystification and
hemorrhage are clearly visible. Tumors become homoge-
neous and hypodense. However, even in highly responsive
tumors, microscopic foci of viable cells are seen either as
isolated tumor cells or as distinct micronodules embedded
in an extensively hyalinized background.
The molecular effects of imatinib on responding GISTs
are currently being explored. Apoptosis (programmed cell
death type I) has been frequently described in GIST cell
lines treated with imatinib mesylate [19,20]; importantly,
McAuliffe et al. [21] indicate that the action of imatinib
may be both cytotoxic (by evidence of apoptosis) and cyto-
static. Recently, autophagy (programmed cell death type
II) has been suggested as a possible alternative mechanism
of response to the imatinib mesylate treatment in clinical
biopsies [22]. Autophagy is the major self-degradative pro-
cess in eukaryotic cells and has multiple physiological
functions, including protein degradation, organelle turn-
over, and response of cancer cells to chemotherapy [23].
In this report, we used a proteomic approach in combi-
nation with other analyses to investigate the protein com-
position of highly responsive, resected GISTs after imatinib
mesylated neoadjuvant therapy. Our aim was to identify
several molecular components of the stroma with expres-
sion patterns possibly related to tumor response/behavior.
Methods
Patients and materials
GIST diagnosis was previously performed according to
currently accepted criteria and confirmed by molecular
analysis demonstrating activating mutations in the KIT
receptor [24]. Tumor characteristics and treatment are
detailed in Table 1. A tumor tissue sample (GIST 1) from
an untreated patient was included in the analysis. Speci-
mens from each patient, verified by histopathology, were
snap-frozen in liquid nitrogen and stored in cryotubes in
liquid nitrogen. The specimens (one sample per case) were
assessed for response to imatinib mesylate treatment based
on the morphological criterion of residual cellularity.
Written informed consent to participate in the study was
obtained from each patient before surgery in accordance
with the ethical guidelines of our institute. Plasma samples
were collected under a protocol approved by our institu-
tional review board and the donors provided written
informed consent.
Protein extraction
Tumor specimens were pulverized in a Mikro-Dismem-
brator II (B. Braun Biotech International, Melsungen,
Germany). The pulverized tissue samples and the cell pel-
lets from cell culture were recovered in ice-cold buffer
containing 50 mM HEPES (pH 7.6), 150 mM NaCl, 10%
glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM EGTA,
10 mM Na4P2O7,1 0 0m MN a F ,1m MP M S F ,1m M
sodium orthovanadate, and Complete Mini protease inhi-
bitors cocktail (Roche, Milan, Italy) according to the man-
ufacturer’s instructions. After 30 min incubation with
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tion for 20 min at 13,000 rpm. Supernatants were
collected and protein quantification was performed with
the BCA™ Protein Assay Kit (Thermo Scientific, Milan,
Italy) according to the manufacturer’s instructions.
One-dimensional SDS-PAGE
Thirty micrograms of total extract from GIST samples
a n do fp l a s m aw e r el o a d e do no n e - d i m e n s i o n a l4 - 1 2 %
NuPAGE
® precast gels (Invitrogen, Milan, Italy). Proteins
were visualized with G250 Coomassie Blue (Bio-Rad,
Milan, Italy) by standard procedures.
In-gel tryptic digestion, matrix-assisted laser desorption/
ionization-time of flight-mass spectrometry (MALDI-TOF-
MS), and peptide mass fingerprinting
For protein profiling, protein bands were excised from
Coomassie-stained preparative gels and processed as pre-
viously described [25]. MALDI-TOF-MS was carried out
using a Voyager-DE STR (Applied Biosystems, Milan,
Italy), equipped with a nitrogen laser (337 nm).
Monoisotopic peptide masses were analyzed using the
Aldente software http://www.expasy.org/tools/. Input was
searched according to: Aldente, UniProtKB/SwissProt;
predefined taxon, Mammalia; Spectrometer internal error
max, 25. Only proteins identified in at least three separate
experiments were considered.
OFFGEL protein fractionation
A preparative-scale OFFGEL was used for isoelectric
focusing of proteins. To perform protein fractionation
according to isoelectric point, the 3100 OFFGEL Fractio-
nator and the OFFGEL Kit 3-10 (Agilent Technologies,
Milan, Italy) were used following the manufacturer’s
instructions [26]. The device was set up for the 24-fraction
separation using the 24 cm-long IPG gel strip with a linear
pH gradient from 3 to 10. The proteins were separated in
a two-phase system consisting of a liquid upper phase
(focusing buffer provided by the supplier) separated in
wells and a lower IPG gel strip phase. The sample was
focused using the recommended method for 24-well OFF-
GEL fractionation with a maximum current of 50 μA. The
separation method consisted of a cooling platform tem-
perature of 15°C with electrical setting parameters of 8,000
V/h, 100,000 V, 200 W, and 50 μA/strip. The focusing was
stopped after the total voltage reached 64 kVh. After
focusing, samples were recovered from each well and
transferred to individual microtubes. Corresponding pro-
tein fractions were purified with the 2-D Clean Up (GE
Healthcare, Milan, Italy) and the protein pellets were
Table 1 Clinical, pathological and molecular characterists of GISTs
Case Anatomical
location
Molecular Status Clinical
response
1
Pathological response
2 Tumor
Sample
Size
3
(cm)
GIST 1 Stomach KIT exon 11 Del 558-563 Non treated Non treated Primary >10
GIST 2 Ileum KIT exon 11 L576P Stable disease >90% of viable cells-non responder Recurrence 2-5
GIST 3 Esophagus KIT exon 11 Del 554-558 In response 10% of viable cells-high responder Primary 5-10
GIST 4 Stomach KIT exon 11 Del 557-558 In response 10% of viable cells-high responder Primary >10
GIST 5 Stomach KIT exon 11 V559D In response 10% of viable cells-high responder Primary >10
GIST6 Stomach PDGRF alpha D842V Unresponsive 25% of viable cells-high responder Recurrence < 2
GIST7 Ileum KIT exon 9 Dup 502-503 Unresponsive >90% of viable cells-non responder Liver
metastasis
5-10
GIST8 Pelvis KIT exon 11 Del 558-560 and
V557C
Unresponsive >5% of viable cells-high responder Liver
metastasis
2-5
GIST9 Stomach PDGFR alpha D842V Unresponsive >90% of viable cells-non responder Primary 2-5
GIST10 Stomach KIT wt Unresponsive >90% of viable cells-non responder Primary >10
GIST11 Stomach KIT Dup P577-K581 Unresponsive >90% of viable cells-non responder Primary 5-10
GIST12 Omentum KIT Dup A502-Y503 and N822K Unresponsive >90% of viable cells-non responder Metastasis < 2
GIST13 Intestin KIT K642E and N822K Unresponsive >90% of viable cells-non responder Primary >10
GIST14 Intestin KIT Del M552-Y553 and E554K In response 50-90% of viable cells-moderate
responder
Recurrence 5-10
GIST15 Stomach KIT K642E In response 50-90% of viable cells-moderate
responder
Metastasis 5-10
GIST16 Intestin KIT Dup 502-503 In response 50-90% of viable cells-moderate
responder
Primary < 2
1 Evaluated on the frozen material used for the proteomic/biochemical analyses [16].
2 According to refs 17 and 18.
3 The size of the tumor was measured considering the maximum diameter.
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dimensional SDS-PAGE. For protein profiling, protein
bands were excised from Coomassie-stained preparative
gels and processed as previously described [25].
Cell culture
The human papillary thyroid carcinoma cell line, TPC1,
was grown adherently in Dulbecco’s Modified Eagle’s
Medium (Gibco, Milan, Italy) supplemented with 10%
fetal bovine serum HyClone (Celbio, Milan, Italy) and
1 mM sodium pyruvate (Lonza, Milan, Italy). Human
Embryonic Kidney (HEK) 293T (ATCC number CRL-
1573) cells were grown adherently in Dulbecco’s Modified
Eagle’s Medium supplemented with 10% fetal bovine
serum and L-glutamine (Lonza).
Conditioned medium concentration
An equal volume (~5 ml) of conditioned medium for
each sample (mock and transfected cells) was loaded
into a spin concentrator (Agilent Technologies) with a
5 kDa molecular weight cut-off and centrifuged at
4,000 rpm and 10°C until samples were concentrated
to a final volume of 150-200 μl. Protein concentration
was determined by BCA assay.
Western blot
An equal amount of protein for each sample (30 μg)
was loaded on a one-dimensional 4-12% NuPAGE
® pre-
cast gel (Invitrogen). Proteins were transferred in
NuPAGE
® transfer buffer (Invitrogen) and 20% ethanol
onto a nitrocellulose membrane (Hybond™-C Super,
Amersham Biosciences, Milan, Italy) and checked for
equal sample loading by Red Ponceau S (Sigma-Aldrich,
Milan, Italy) staining. Blots were blocked for 1 h with
TBS (10 mM Tris-HCl [pH 7.5], 150 mM NaCl) plus
0.1% Tween 20 (TBS-T buffer) containing 1% bovine
serum albumin (Sigma-Aldrich) and 3% ovalbumin
(Sigma-Aldrich), then hybridized in the same buffer
with specific antibodies at 4°C overnight using the
recommended dilutions. After incubation, the blots
were washed in TBS-T buffer and incubated for 1 h at
room temperature in previously described buffer using
appropriate secondary antibodies (1:4,000). After incu-
bation, the blots were washed in TBS-T buffer, and
immunoreactive proteins were visualized using an
enhanced ECL system (ECL
® Western blotting detec-
tion reagents, GE Healthcare Life Sciences, Milan, Italy)
according to the manufacturer’s protocol. Monoclonal
mouse anti-human SCGF/CLEC11a antibody was sup-
plied by R&D Systems (Milan, Italy). The ECL
® anti-
mouse IgG, horseradish peroxidase-linked whole anti-
body from sheep was obtained from GE Healthcare Life
Sciences.
Immunohistochemistry
Immunohistochemistry was performed on 2-μm formalin-
fixed and paraffin-embedded sections of representative
tumoral areas deparaffined in xylene and rehydrated in
graded alcohols. Endogenous peroxidase activity was
blocked by treatment for 10 min with 0.3% hydrogen per-
oxide in distilled water. Antigen retrieval was obtained by
autoclaving for 15 min.
The slides were cooled under tap water, washed three
times in 0.05 M phosphate-buffered saline plus 0.1%
Triton, and incubated with ultra v-block (Lab Vision
Corp, Newmarker, UK) for 10 min at room temperature.
Then, they were incubated at room temperature for 1 h
with the monoclonal mouse anti-human SCGF/CLEC11a
antibody (R&D Systems) diluted 1:400 in citrate buffer
(pH 6). The slides were washed again three times in 0.05
M phosphate-buffered saline plus 0.1% Triton and devel-
oped using the Ultra Vision LP Volume Detection System
(Lab Vision Corp). After washes in 0.05 M phosphate-buf-
fered saline, peroxidase activity was detected with diami-
nobenzidine for 10 min in the dark. The slides were
counterstained with hematoxylin. Immunohistochemical
analysis for KIT was performed using an antibody against
CD117, as previously described [27]. Positivity was defined
as the detection of immunopositivity in >90% of cells.
Plasmid construction
Total RNA of the TPC1 cell line was prepared using a
TRIZOL reagent (Life Technologies, Italy), the oligo(dT)-
primed cDNA was synthesized using a RT-PCR kit (Stra-
tagene, Milan, Italy). Oligonucleotides 5’-CCAAGCTTTC-
CAGCTTAATGCAG-3’(forward) and 5’-TAAAGCGGC
CGCCCCGCTAGAA-3’(reverse) were used in PCR to
amplify the full human SCGF- a (hSCGF-a,U n i P r o t
accession number Q9Y240) sequence. Taq Phusion
® High
Fidelity DNA polymerase (Finnzymes, Espoo, Finland) was
used with the following thermal cycling conditions: initial
denaturation at 98°C for 30 sec; 35 cycles of denaturation
at 98°C for 10 sec, annealing at 60°C for 30 sec, extension
at 72°C for 40 sec; and final extension at 72°C for 7 min.
The hSCGF-a cDNA was subcloned into the pcDNA3.1
plasmid vector (Invitrogen). The plasmid expressing
hSCGF-b was obtained by mutagenesis of the plasmid
expressing hSCGF-a using the Quick-Change
® II XL Site-
Directed Mutagenesis Kit (Stratagene, Milan, Italy),
according to the manufacturer’sp r o t o c o l .T h eD N A
sequences contained in both vectors were checked by
automatic sequencing.
Cell transfection
HEK 293T cells were transiently transfected by calcium
phosphate precipitation, as previously described [28],
with the pcDNA3 expression vector (Invitrogen) alone
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SCGF-b.
Removal of O-linked oligosaccharides from SCGF
Suitable amounts (based on western blotting with anti-
SCGF) of cell and tissue protein extracts and secreted pro-
teins were incubated at 37°C for 4 h with O-glycosidase
(Sigma-Aldrich) and a(2®3,6,8,9)neuraminidase (sialidase,
Sigma-Aldrich) according to the manufacturer’s protocol.
The digested samples were analyzed by western blotting
with anti-SCGF.
Results
To explore the protein expression pattern of GIST samples
treated with imatinib mesylate, protein extracts from five
GISTs were loaded onto one-dimensional SDS-PAGE and
visualized by Coomassie staining. These five samples con-
sisted of one untreated tumor (GIST 1), three tumors from
high-responder patients (GISTs 3-5), and one tumor (GIST
2) from a patient with clinically stable disease but who was
scored as a non-responder (Table 1). The protein patterns
of the highly responsive tumors (Figure 1, lanes C-E) were
uniform and contained fewer protein bands than the other
samples (Figure 1, lanes A and B). The staining patterns of
the GIST samples did not differ consistently from that of a
pool of plasma samples from healthy donors (Figure 1, lane
F). MS of gel bands obtained after OFFGEL fractionation
of the extracts (data not shown) confirmed that the major-
ity of proteins were blood components (Table 2).
In the GIST 5 extract, Coomassie staining revealed
bands (bands 8-10 in Figure 1A, lane E, and Figure 1B)
that were not present in the plasma sample. Bands 8 and
9 corresponded to SCGF, also known as C-type lectin
domain family member 11A (CLEC11A), an important
hematopoietic growth factor with burst-promoting activ-
ity for human bone marrow erythroid progenitors [29].
Band 10 corresponded to C1q, the initiator of the classi-
cal complement cascade [30].
Western blotting with anti-SCGF antibody confirmed
the presence of SCGF-positive bands in GIST 5 extract (b
and c in Figure 2, lane B) and highlighted the presence of
a third isoform of ~46 kDa (a in Figure 2, lane B) that was
not detected by the proteomic analysis. All three isoforms
were undetectable in a plasma sample (Figure 2, lane C),
consistent with the observation that the SCGF plasma
concentration was too low to be analyzed by western blot.
In the peripheral blood of adults, SCGF concentration can
only be detected by enzyme-linked immunosorbent assay
because the concentration is approximately 10-20 ng/ml
[31]. Using Coomassie staining to visualize the electro-
phoresed SCGF proteins, we estimated at least 60 ng of
protein in the GIST 5 sample. Since 30 μg of tissue extract
was analyzed, we calculated the SCGF concentration to be
0.5 ng/μg in the GIST extract, which was much more
protein than would be present in an equivalent amount of
plasma protein (0.03-2 pg/μg).
To assess the possible origin and localization of SCGF,
we performed immunohistochemistry on all five GIST
samples. GIST 5 (Figure 3B) displayed a strong SCGF
positivity, consistent with the western blot, that was
restricted to the stroma compartment. The rare viable
tumoral cells present in the responding area were negative
in the cytoplasm and the nucleus. However, these cells
retained weak cytoplasmic KIT reactivity (Figure 3C). The
r e s p o n d i n gc a s e s( G I S T s3a n d4 )a n dt h en a ï v eG I S T
(GIST 1) were negative (Additional file 1 and data not
shown). Interestingly, GIST 2 (Figure 3D-F) exhibited
minimal areas of regression that were mostly depleted of
tumoral cells and were SCGF-positive and KIT-negative.
RT-PCR did not reveal the presence of SCGF transcripts
in responding or non-responding GISTs (Additional
file 2), corroborating the hypothesis that blood is likely
the source of SCGF.
SCGF is a largely uncharacterized hematopoietic media-
tor that promotes enhanced erythroid progenitor formation
from human bone marrow [32]. Stem cell transplantation-
elevated serum SCGF levels are associated with enhanced
hematopoietic recovery [32], and the differentiation of
dendritic cells in mature type I inflammatory cells is
accompanied by an increase in SCGF secretion [1]. Based
on these observations, we hypothesized that an inflamma-
tory reaction induced by imatinib treatment could be
responsible for the SCGF positivity we observed in our
GIST specimens. We therefore employed immunohisto-
chemistry to investigate the presence of macrophage/den-
dritic cells using anti-CD68 antibodies in samples GIST 2
and 5. Interestingly, we observed areas of CD68 positivity
in GIST 5, while GIST 2 presented a diffuse infiltration of
CD68-positive macrophages. In both cases the correspond-
ing stromal counterpart was SCGF-positive (Figure 4).
In order to test the consistency of the relationship
between SCGF expression and the histological response
to imatinib, we analyzed SCGF expression in tumor areas
scored as acellular or with <10% residual tumoral cells
and in those areas scored as non-responsive or scarcely
responsive in three imatinib-treated patients (GISTs 6, 7
and 8 in Table 1). Figure 5A summarizes the results
obtained in a comparative analysis of non-affected and
affected tumor areas: the hematoxylin-eosin staining of
the histological sections (panels 1-3; 6-8; and 11-13); the
images of the protein lysates prepared from adjacent
tumor areas that were separated onto SDS gels and
stained with Coomassie-blu (panels 4, 9 and 14); and, the
western blotting of the same protein lysates probed by
with anti-SCGF antibody (panels 5, 10 and 15). Lysates
from imatinib-affected areas displayed a simplified pro-
tein band profile; notably, the anti-SCGF antibody recog-
nized an SCGF-related band in protein lysates from
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Page 5 of 13Figure 1 Protein expression in GISTs from patients treated with imatinib mesylate. A) SDS-PAGE (4-12% bis-Tris gel) of total protein
extracts from three highly responsive GIST patients (lanes C-E) and from one poorly responsive patient with stable disease (lane B). A tumor
tissue sample from an untreated GIST patient is shown as the control (lane A). A pool of plasma samples from healthy subjects (lane F) is shown
for comparison with GIST extracts. Lanes G and H demonstrate the protein coverage of SCGF isoforms assessed by MALDI-TOF-MS of tryptic
peptides obtained from digestion of the proteins in bands 8 and 9, respectively. The boxed sequences correspond to the sequence without
signal peptide (amino acids 1-21) of SCGF-a (Q9Y240) that is available in the Aldente (ExPASy Proteomics Server) database. Capital letters
indicate the sequence detected by MS, while the underlined sequence indicates the 78 amino acids that are lacking in the b-form. Bold
numbers denote the proteins identified by MS and listed in panel B. B) Proteins identified in GIST 5 (lane E) after SDS-PAGE fractionation, tryptic
digest, and MALDI-TOF-MS.
1Number refers to the specific band position on the SDS-PAGE in Figure 1A, lane E.
2Swiss-Prot/TrEMBL accession
line.
3Swiss-Prot/TrEMBL description line.
4Theoretical protein mass.
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matched non-responsive or scarcely responsive areas
(Figure 5A). These observations strongly support a rela-
tionship between SCGF positivity and low cellularity due
to imatinib activity. In addition, we noted the presence of
inflammatory cell infiltrate in the hematoxylin-eosin sec-
tion of the responding area of GIST 6 (panels 2 and 3), of
scattered lymphocytes in the hematoxylin-eosin section
of the responding area of GIST 7 (panels 7 and 8), and of
monocytes/macrophages in the hematoxylin-eosin sec-
tion of the responding area of GIST 8 (panels 12 and 13).
One SCGF-related signal was also detected by western
blot in responding GISTs 14 and 16, but not in respond-
ing GIST 15 and non-responding GISTs 9-13 (Table 1
and Figure 5B).
SCGF is a secreted cytokine expressed in two distinct
forms; SCGF-a is the full size form (323 amino acids,
Table 2 List of proteins identified after OFFGEL and SDS-
PAGE fractionation, tryptic digest, and MALDI-TOF MS
analysis
No. AC
1 DE
2 Mw
3 pI
4 Cov
5
1 P01009 Alpha-1-antitrypsin 44 5.4 47
2 P04217 Alpha-1B-glycoprotein 52 5.6 38
3 P02750 Leucine-rich alpha-2-glycoprotein 34 5.7 22
4 P01023 Alpha-2-macroglobulin 161 5.9 28
5 P01011 Alpha-1-antichymotrypsin 45 5.3 32
6 P60709 Actin, cytoplasmic 1 42 5.3 65
7 P63261 Actin, cytoplasmic 2 42 5.3 65
8 P43652 Afamin 67 5.6 42
9 P02768 Serum albumin 66 5.7 66
10 P01008 Antithrombin-III 49 6.0 30
11 P08758 Annexin A5 36 4.9 69
12 P02647 Apolipoprotein A-I 28 5.3 74
13 P06727 Apolipoprotein A-IV 43 5.2 43
14 P00450 Ceruloplasmin 120 5.4 15
15 P00751 Complement factor B 83 6.7 36
16 P08603 Complement factor H 137 6.1 46
17 P01024 Complement C3 185 6.0 11
18 P0C0L4 Complement C4b-A 84 5.3 21
19 P0C0L5 Complement C4b-B 84 5.4 21
20 P02765 Alpha-2-HS-glycoprotein chain A 30 4.5 32
21 P02679 Fibrinogen gamma chain 48 5.2 33
22 P02792 Ferritin light chain 20 5.5 45
23 P68871 Hemoglobin subunit beta 16 6.8 84
24 P00738 Haptoglobin 43 6.1 40
25 P08238 Heat shock protein HSP 90-beta 83 5.0 24
26 P07900 Heat shock protein HSP 90-alpha 85 4.9 18
27 P01876 Ig alpha-1 chain C region 38 6.1 29
28 P01857 Ig gamma-1 chain C region 36 8.5 28
29 P01859 Ig gamma-2 chain C region 36 7.7 26
30 P19827 Inter-alpha-trypsin inhibitor heavy
chain
71 6.3 17
31 P13645 Keratin, type I cytoskeletal 10 60 5.1 24
32 P35527 Keratin, type I cytoskeletal 9 62 5.2 16
33 P04264 Keratin, type II cytoskeletal 1 66 8.2 26
34 P01042 Kininogen-1 70 6.2 22
35 P00734 Prothrombin 65 5.2 50
36 P02787 Serotransferrin 75 6.7 47
37 P02766 Transthyretin 14 5.4 80
38 P02774 Vitamin D-binding protein 51 5.2 53
39 P25311 Zinc-alpha-2-glycoprotein 32 5.6 22
1 Swiss-Prot/TrEMBL accession line.
2 Swiss-Prot/TrEMBL description line.
3 Theoretical protein mass.
4 Theoretical protein isoelectric point.
5 Number of amino acids present in at least one peptide over the number of
amino acids of the protein.
Figure 2 Western blotting of SCGF expression. Western blotting
with anti SCGF-a/-b antibody of tumor tissue samples from the
untreated GIST 1 patient (lane A), the SCGF-positive GIST 5 patient
(lane B), a pool of plasma samples from healthy subjects (lane C), and
the cell extract (lane D) and conditioned medium (lane E) from the
TPC1 cell line. (a) indicates the mature and secreted form of SCGF-a
detected in the GIST 5 sample (lane B) and in the TPC1 conditioned
medium (lane E); (b) indicates the immature and cytoplasmatic form
of SCGF-a detected in the GIST 5 sample (lane B; corresponding to
band 8 in Figure 1A) and in the TPC1 cell extract (lane D); (c) points
out the quantitatively most relevant form, exclusively present in the
GIST 5 sample, corresponding to band 9 in Figure 1A.
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Page 7 of 1335,695 Da), while SCGF-b is the shorter form (245
amino acids, 26,902 Da) characterized by a deletion
within a conserved carbohydrate recognition domain
[33]. These theoretical masses only partially explain
the observed molecular weights in electrophoretic
separations. The spectra from our MALDI-TOF-MS of
tryptic peptides from two SCGF-positive bands (band 8
and 9 in Figure 1, lane E) were nearly identical in size
and were attributed to the a form (lanes G and H in
Figure 1A).
Figure 3 Immunohistochemistry of SCGF expression in GIST samples. A) Hematoxylin-eosin section of one representative slide from GIST 5.
B) SCGF staining; strong SCGF positivity, consistent with western blotting, was restricted to the stroma compartment. C) CD117 staining; cells
retained weak cytoplasmic KIT reactivity. The rare viable tumoral cells present in the responding area were SCGF-negative in the cytoplasm and
the nucleus. D) Hematoxylin-eosin section of one representative slide from GIST 2. Highly cellulated areas indicating the absence of pathological
response are visible. Only two areas showing rare tumoral cells are present. E) CD117 staining; all cellulated areas exhibit strong KIT expression
not observed in the acellulated areas mostly composed of stroma. F) SCGF staining; strong SCGF expression is restricted to the non-cellulated
areas, in contrast to CD117 staining.
Figure 4 Immunohistochemistry of CD68 and SCGF in GIST 5 and GIST 2. A) Hematoxilin-eosin section of one representative slide from
GIST 5. B) CD68 staining; CD68 positive macrophages are scattered through the section. C) SCGF staining; SCGF positivity was observed in the
corresponding stromal area. D) Hematoxylin-eosin section of one representative slide from GIST 2. E) CD68 staining; a diffuse infiltration of CD68-
positive macrophages is visible in this area. F) SCGF staining; SCGF positivity was observed in the corresponding stromal counterpart.
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sulphated, we deglycosylated the GIST 5 lysate to deter-
mine the sizes of SCGF bands before and after digestion.
The immunoreactive band with the highest molecular
weight (band a in Figure 6, lane 1) completely disappeared
after deglycosylation; the intermediate band (band b in
Figure 6, lane 1) remained unmodified, and the lowest
band (band c in Figure 6, lane 1) exhibited an appreciable,
apparently incomplete reduction in its molecular weight
(band d in Figure 6, lane 2). Isoform a also occurred in
conditioned medium (Figure 6, lane 4), as compared with
isoforms expressed by the TPC1 cell line (Figure 6, lanes
3-5). Isoform a was equivalent to the fully glycosylated
and secreted form, while the low-molecular weight iso-
form in the cell extract (band b in Figure 6, lanes 3 and 5)
was equivalent to an immature, cytoplasmatic, unglycosy-
lated form. Interestingly, we observed SCGF positivity for
the isoforms corresponding to bands a and b in Figure 2,
which were also observed in the conditioned medium
(Figure 2, lane E) and in the cell extract (Figure 2, lane D)
of the TPC1 cell line.
To further define the nature of SCGF isoforms
expressed in the GIST 5 sample, we tested the possibility
that the other form corresponded to isoform b.W e
Figure 5 Analysis of an independent set of imatinib-treated GIST samples. A) Comparative analysis of tumoral areas from of GIST 6, 7 and
8, which resulted non-responding or responding to imatinib treatment. Panels 1-5, 6-10 and 11-15 refer to GISTs 6, 7 and 8 respectively. Panels
1, 6 and 11 represent non-responding areas; panels 2, 7 and 12 responding areas; panels 3, 8 and 13 show the inset areas of panels 2, 7, and 12.
Arrows and arrowheads indicate inflammatory macrophages and lymphocytes, respectively, and asterisks residual tumor cells. Panels 4, 9 and 14
show the protein lysates prepared from adjacent tumor areas were separated onto SDS gels and stained with Coomassie-blu. Lane NR indicates
the non-responding area and lane R indicates the responding area. Panels 5, 10 and 15 show NR and R protein lysates were probed with anti-
SCGF and anti-actin antibodies, respectively. Note that in panels 5, 10 and 15 arrows refer to the actin band that is detected as a non-specific
background band in anti-SCGF blot. As expected, due to the higher cellularity we observe a more intense actin band in NR samples than in R
samples. B) Western blotting of SCGF expression in GIST 9-16 samples. GIST 9-13 represent protein lysates from non-responder GIST samples and
GIST 14-16 protein lysates from responder samples. C corresponds to GIST 6 protein lysate. Samples were probed with both anti-SCGF and anti-
actin antibodies. Arrow indicates actin band and asterisks SCGF band. In non-responder samples anti-SCGF detected exclusively the actin band.
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Page 9 of 13transfected the HEK293 cell line that scored negative for
SCGF proteins (Figure 6, lanes 6 and 7) with SCGF-b
cDNA. Western blotting detected a protein with the size
expected for the SCGF-b backbone (Figure 6, lanes 8-10)
that did not correspond to band d of the GIST 5 sample
(Figure 6, lane 2). Thus, we concluded that band d was
not the SCGF-b form.
Discussion
Few studies have correlated clinical response with histo-
logical response in GISTs after prolonged imatinib treat-
ment. However, it is widely recognized that clinical
outcome in stable or partially responsive GIST patients
does not seem to be influenced by the duration of imati-
nib treatment, the histological response, or the size of
the tumor [18]. In this study, we analyzed the proteo-
mic, histological, immunohistochemical, and clinical
features of a small group of GISTs resected after pro-
longed imatinib treatment.
SCGF, a novel cytokine, exerts its action on primitive
hematopoietic progenitor cells. In combination with other
hematopoietic growth factors such as granulocyte-macro-
phage colony-stimulating factor and erythropoietin, SCGF
stimulates the formation of erythroid and granulocyte/
macrophage colonies, although SCGF alone cannot induce
colony formation [29]. Using a proteomic approach, we
detected a large amount of SCGF in the protein extract of
one imatinib-treated GIST sample (Figure 1). This sample
also had a residual cell component of <10% and was nega-
tive or very slightly positive for CD117 staining. Biochem-
ical analyses revealed the presence of a small number of
KIT receptors with very low activation (data not shown). In
parallel, we found extensive SCGF positivity in the abun-
dant stromal component, which appeared homogenous,
Figure 6 Western blotting of SCGF after deglycosylation. Western blotting with anti-SCGF-a/-b antibody. Lanes 1 and 2 compare SCGF
patterns in the untreated (lane 1) and the deglycosylated (lane 2) protein extract of the GIST 5 sample. Lanes 3-5 contain a comparison of the
cytoplasmatic (lane 3) and the secreted (lane 4) SCGF-a forms and the untreated (lane 4) and the deglycosylated secreted (lane 5) SCGF-a forms
in the TPC1 cell line. Lanes 6 and 7 depict the expression of SCGF-a and -b in the cell extract and conditioned medium of a mock HEK293 cell
line (negative control). Lanes 8-10 reflect SCGF-b expression in the cell extract (lane 8) and conditioned medium (lane 9) of the transfected
HEK293 cell line; lanes 8 and 10 show the untreated and the deglycosylated SCGF-b forms in the transfected HEK293 cell line extract. The
mature and secreted forms of SCGF-a detected in the GIST 5 sample (lane 1) and the TPC1 conditioned medium (lane 4) are indicated by (a);
(b) indicates an immature, cytoplasmatic, unglycosylated form of SCGF-a in the untreated (lane 1) and deglycosylated (lane 2) GIST 5 samples,
and in the cell extract (lane 3) and conditioned medium of the TPC1 cell line after deglycosylation (lane 5); the form indicated by (c) was
exclusively detected in the GIST 5 sample, was the quantitatively most relevant form in the untreated sample (lane 1), and was observed after
deglycosylation (lane 2); (d) indicates the form exclusively detected and quantitatively most relevant in the deglycosylated GIST 5 sample (lane
2), corresponding to the protein backbone of SCGF-a (~36 kDa); (e) indicates the form detected in the untreated (lane 8) and deglycosylated
(lane 10) cell extract of the transfected HEK293 cell line, corresponding to the primary structure of SCGF-b (~27 kDa).
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Page 10 of 13hypodense, and eosinophilic. This observation was repli-
cated in part of the progressive lesion of another treated
GIST case in which we identified strong SCGF positivity
exclusively in CD117-negative areas. Interestingly, SCGF
expression occurred in the imatinib-affected areas of three
GISTs that was not detected in the unaffected or scarcely
affected areas of the same tumors; SCGF-positive bands
were also identified in two out three responding tumors
but were absent in tumors from five non-responder
patients.
A study carried out on in vivo material demonstrated
that SCGF is strongly expressed in bone marrow and only
faintly in lymphoid organs; in bone marrow, SCGF is con-
centrated in the cytoplasm of immature neutrophils, but
not in myeloblasts, mature neutrophils, or the extracellular
bone marrow fluid [34]. Since immature neutrophils play a
role in tumor-induced immuno-inflammatory responses,
SCGF may impact mechanisms regulating these responses.
These observations are consistent with RNA expression
patterns in mouse and human protein-encoding transcrip-
tomes [35] and are attributed as follows: high expression
levels to CD34+ cells, low expression levels to CD33+
(myeloid) cells, cardiomyocytes, and smooth muscle cells,
and very low expression levels to all other cell lines or
tissues.
Hiraoka [36] recently demonstrated that leukemia cell
lines require self-secreted SCGF for their proliferation in
tumors, indicating a putative autocrine SCGF mechan-
ism, and that loop blockage with neutralizing antibody
prevents extracellular SCGF from inducing apoptosis.
Levina et al. [37] demonstrated that the high tumorigenic
and metastatic potentials of lung cancer stem cells corre-
lated with superior production of angiogenic factors and
growth factors involved in cell proliferation and angio-
genesis, describing increased levels of SCGF, stroma-
derived factor 1a, and SCF in tumors from cancer stem
cells in association with the stem cell phenotype. Gene-
expression profiles from 35 childhood acute lymphoblas-
tic leukemia matched diagnosis/relapse pairs, as well as
60 uniformly treated children at relapse, indicated that
SCGF is significantly overexpressed at relapse [38].
The presence of SCGF in the CD117-negative stromal
compartment of imatinib-treated GISTs suggests that its
expression is associated with the histological response of
GISTs to imatinib therapy. Our RT-PCR investigation
revealed that SCGF is not actively transcribed in GIST
samples, and thus it is difficult to determine the possible
sources of SCGF in these specimens. A recent study
described a subgroup of GISTs surgically resected after
neoadjuvant imatinib treatment that exhibited reduced
numbers of tumor cells in the hypocellular myxohyaline
stroma, with small numbers of scattered atypical nuclei
and occasional stromal hemorrhages [39]. A separate
investigation assessed a GIST case treated with imatinib
therapy for four weeks in which most of the tumor cells
were replaced by myxoid stroma and the remaining tumor
cells did not appear to be actively dividing [40]. However,
to date no study has reported data on SCGF in GIST
samples.
In our study, SCGF appeared as part of the stromal
GIST component and, in particular, as part of the eosino-
philic proteinaceous matrix described as myxoid, collage-
nous, or hyaline. Our proteomics experiment uncovered
high plasma-protein content in treated tumors, and
immunohistochemistry revealed the SCGF positivity in
CD117-negative and CD68-positive areas. These observa-
tions could link SCGF positivity with the imatinib-
induced inflammatory response that elicits monocyte/
macrophage tissue migration, promoting scarring and
removal of cell debris. CD68 positivity confirms macro-
phage infiltration, which may also explain the high level
of C1q [41] in our GIST 5 proteomic analysis. Recent
data support the hypothesis that induced type I matura-
tion of dendritic cells is associated with a peak of SCGF
production [1], supporting a pro-inflammatory role for
this cytokine. It is therefore plausible that these are
immunological reactions, and that liquidation of the dead
tumor cells via macrophages leads to lesion shrinkage.
Conclusions
SCGF function may be related to the imatinib-induced
inflammation response in responding GIST patients.
Further studies are necessary to identify the receptor of
this cytokine, to further clarify its origin, and to deter-
mine the reason for its accumulation in some imatinib-
treated GISTs. These investigations may answer funda-
mental questions about the composition of the stromal
matrix after imatinib therapy and identify proteins related
to desirable tumor response/behavior.
Additional material
Additional file 1: Hematoxylin-eosin sections of representative
slides from GIST 1, 3 and 4.
Additional file 2: Espression of SCGF RNA in GIST samples 3, 4 and 5.
Acknowledgements
This study was supported by grants from the Associazione Italiana per la
Ricerca sul Cancro (AIRC, Milan, Italy) and Alleanza Contro il Cancro (ACC).
We thank Ms. Mazzadi Cristina for secretarial assistance.
Author details
1Proteomics Laboratory, Department of Experimental Oncology and
Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan,
Italy.
2Experimental Molecular Pathology, Department of Pathology,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
3Department of
Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan,
Italy.
4Unit of Immunotherapy of Human Tumors, Department of
Experimental Oncology Fondazione IRCCS Istituto Nazionale dei Tumori,
Milan, Italy.
5Department of Surgery, Fondazione IRCCS Istituto Nazionale dei
Da Riva et al. Journal of Translational Medicine 2011, 9:158
http://www.translational-medicine.com/content/9/1/158
Page 11 of 13Tumori, Milan, Italy.
6Scientific Directorate, Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan, Italy.
Authors’ contributions
LDV, FB, and IB planned the study and drafted the manuscript; FB, VH, AG,
FM, ET, EF and MAP contributed to the design of the study and critically
revised the manuscript; LDV, PM, FB, FM, Eva T, and EV performed western
blotting and immunohistochemical experiments; SP contributed to data
analysis. All the authors have read and approved the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 11 May 2011 Accepted: 23 September 2011
Published: 23 September 2011
References
1. Gundacker NC, Haudek VJ, Wimmer H, Slany A, Griss J, Bochkov V, et al:
Cytoplasmic Proteome and Secretome Profiles of Differently Stimulated
Human Dendritic Cells. Journal of Proteome Research 2009, 8:2799-2811.
2. Dematteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF: Two
hundred gastrointestinal stromal tumors: recurrence patterns and
prognostic factors for survival. Ann Surg 2000, 231:51-58.
3. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G:
Management of malignant gastrointestinal stromal tumours. Lancet
Oncol 2002, 3:655-664.
4. Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B,
et al: Gastrointestinal stromal tumors: the incidence, prevalence, clinical
course, and prognostication in the preimatinib mesylate era–a
population-based study in western Sweden. Cancer 2005, 103:821-829.
5. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM: Gastrointestinal
pacemaker cell tumor (GIPACT) - Gastrointestinal stromal tumors show
phenotypic characteristics of the interstitial cells of Cajal. American
Journal of Pathology 1998, 152:1259-1269.
6. Corless CL, Fletcher JA, Heinrich MC: Biology of gastrointestinal stromal
tumors. J Clin Oncol 2004, 22:3813-3825.
7. Williams DE, Eisenman J, Baird A, Rauch C, Vanness K, March CJ, et al:
Identification of A Ligand for the C-Kit Protooncogene. Cell 1990,
63:167-174.
8. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, et al:
Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase
for an unidentified ligand. EMBO J 1987, 6:3341-3351.
9. Zsebo KM, Wypych J, McNiece IK, Lu HS, Smith KA, Karkare SB, et al:
Identification, purification, and biological characterization of
hematopoietic stem cell factor from buffalo rat liver–conditioned
medium. Cell 1990, 63:195-201.
10. Theou-Anton N, Tabone S, Brouty-Boye D, Saffroy R, Ronnstrand L,
Lemoine A, et al: Co expression of SCF and KIT in gastrointestinal stromal
tumours (GISTs) suggests an autocrine/paracrine mechanism. Br J Cancer
2006, 94:1180-1185.
11. Miettinen M, Lasota J: KIT (CD117): a review on expression in normal and
neoplastic tissues, and mutations and their clinicopathologic correlation.
Appl Immunohistochem Mol Morphol 2005, 13:205-220.
12. Rubin BP, Heinrich MC, Corless CL: Gastrointestinal stromal tumour (vol
369, pg 1731, 2007). Lancet 2007, 370:388.
13. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al:
Progression-free survival in gastrointestinal stromal tumours with high-
dose imatinib: randomised trial. Lancet 2004, 364:1127-1134.
14. van GM, Verweij J, Casali PG, Le CA, Hohenberger P, Ray-Coquard I, et al:
Initial and late resistance to imatinib in advanced gastrointestinal
stromal tumors are predicted by different prognostic factors: a European
Organisation for Research and Treatment of Cancer-Italian Sarcoma
Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005,
23:5795-5804.
15. Scaife CL, Hunt KK, Patel SR, Benjamin RS, Burgess MA, Chen LL, et al: Is
there a role for surgery in patients with “unresectable” cKIT+
gastrointestinal stromal tumors treated with imatinib mesylate? Am J
Surg 2003, 186:665-669.
16. Choi H: Response evaluation of gastrointestinal stromal tumors.
Oncologist 2008, 13:4-7.
17. Miselli F, Casieri P, Negri T, Orsenigo M, Lagonigro MS, Gronchi A, et al:
c-Kit/PDGFRA gene status alterations possibly related to primary
imatinib resistance in gastrointestinal stromal tumors. Clinical Cancer
Research 2007, 13:2369-2377.
18. Agaram NP, Besmer P, Wong GC, Guo TH, Socci ND, Maki RG, et al:
Pathologic and molecular heterogeneity in imatinib-stable or imatinib-
responsive gastrointestinal stromal tumors. Clinical Cancer Research 2007,
13:170-181.
19. Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S,
et al: Mechanisms of oncogenic KIT signal transduction in primary
gastrointestinal stromal tumors (GISTs). Oncogene 2004, 23:3999-4006.
20. Bauer S, Duensing A, Demetri GD, Fletcher JA: KIT oncogenic signaling
mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-
kinase/AKT is a crucial survival pathway. Oncogene 2007, 26:7560-7568.
21. McAuliffe JC, Hunt KK, Lazar AJ, Choi H, Qiao W, Thall P, et al: A
randomized, phase II study of preoperative plus postoperative imatinib
in GIST: evidence of rapid radiographic response and temporal
induction of tumor cell apoptosis. Ann Surg Oncol 2009, 16:910-919.
22. Miselli F, Negri T, Gronchi A, Losa M, Conca E, Brich S, Fumagalli E, Fiore M,
Casali PG, Pierotti MA, et al: Is autophagy rather than apoptosis the
regression driver in imatinib-treated gastrointestinal stromal tumors?
Transl Oncol 2008, 1:177-186.
23. Klionsky DJ, Emr SD: Autophagy as a regulated pathway of cellular
degradation. Science 2000, 290:1717-1721.
24. Casali PG, Blay JY: Gastrointestinal stromal tumours: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Annals of
Oncology 2010, 21:v98-v102.
25. Gorla L, Mondellini P, Cuccuru G, Micciche F, Cassinelli G, Cremona M, et al:
Proteomics Study of Medullary Thyroid Carcinomas Expressing RET
Germ-Line Mutations: Identification of New Signaling Elements. Molecular
Carcinogenesis 2009, 48:220-231.
26. Michel PE, Crettaz D, Morier P, Heller M, Gallot D, Tissot JD, et al: Proteome
analysis of human plasma and amniotic fluid by Off-Gel (TM) isoelectric
focusing followed by nano-LC-MS/MS. Electrophoresis 2006, 27:1169-1181.
27. Perrone F, Tamborini E, Dagrada GP, Colombo F, Bonadiman L, Albertini V,
et al: 9p21 Locus analysis in high-risk gastrointestinal stromal tumors
characterized for c-kit and platelet-derived growth factor receptor alpha
gene alterations. Cancer 2005, 104:159-169.
28. Mercalli E, Ghizzoni S, Arighi E, Alberti L, Sangregorio R, Radice MT, et al:
Key role of Shc signaling in the transforming pathway triggered by Ret/
ptc2 oncoprotein. Oncogene 2001, 20:3475-3485.
29. Hiraoka A, Sugimura A, Seki T, Nagasawa T, Ohta N, Shimonishi M, et al:
Cloning, expression, and characterization of a cDNA encoding a novel
human growth factor for primitive hematopoietic progenitor cells.
Proceedings of the National Academy of Sciences of the United States of
America 1997, 94:7577-7582.
30. Kojouharova M, Reid K, Gadjeva M: New insights into the molecular
mechanisms of classical complement activation. Molecular Immunology
2010, 47:2154-2160.
31. Ito C, Sato H, Ando K, Watanabe S, Yoshiba F, Kishi K, et al: Serum stem
cell growth factor for monitoring hematopoietic recovery following stem
cell transplantation. Bone Marrow Transplantation 2003, 32:391-398.
32. Hiraoka A, Yano KK, Kagami N, Takeshige K, Mio H, Anazawa H, et al: Stem
cell growth factor: in situ hybridization analysis on the gene expression,
molecular characterization and in vitro proliferative activity of a
recombinant preparation on primitive hematopoietic progenitor cells.
Hematol J 2001, 2:307-315.
33. Mio H, Kagami N, Yokokawa S, Kawai H, Nakagawa S, Takeuchi K, et al:
Isolation and characterization of a cDNA for human, mouse, and rat full-
length stem cell growth factor, a new member of C-type lectin
superfamily. Biochemical and Biophysical Research Communications 1998,
249:124-130.
34. Perrin C, Bayle J, Bannwarth S, Michiels JF, Heudier P, Lefebvre JC, et al:
Expression of LSLCL, a new C-type lectin, is closely restricted, in bone
marrow, to immature neutrophils. C R Acad Sci III 2001, 324:1125-1132.
35. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, et al: A gene atlas
of the mouse and human protein-encoding transcriptomes. Proc Natl
Acad Sci USA 2004, 101:6062-6067.
36. Hiraoka A: Leukemia cell lines require self-secreted stem cell growth
factor (SCGF) for their proliferation. Leukemia Research 2008, 32:1623-1625.
Da Riva et al. Journal of Translational Medicine 2011, 9:158
http://www.translational-medicine.com/content/9/1/158
Page 12 of 1337. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE: Drug-selected
human lung cancer stem cells: cytokine network, tumorigenic and
metastatic properties. PLoS One 2008, 3:e3077.
38. Bhojwani D, Kang HN, Moskowitz NP, Min DJ, Lee H, Potter JW, et al:
Biologic pathways associated with relapse in childhood acute
lymphoblastic leukemia: a Children’s Oncology Group study. Blood 2006,
108:711-717.
39. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B,
Roberts PJ, et al: Efficacy and safety of imatinib mesylate in advanced
gastrointestinal stromal tumors. New England Journal of Medicine 2002,
347:472-480.
40. Joensuu H, Dimitrijevic S: Tyrosine kinase inhibitor imatinib (STI571) as an
anticancer agent for solid tumours. Annals of Medicine 2001, 33:451-455.
41. Sontheimer RD, Racila E, Racila DM: C1q: its functions within the innate
and adaptive immune responses and its role in lupus autoimmunity. J
Invest Dermatol 2005, 125:14-23.
doi:10.1186/1479-5876-9-158
Cite this article as: Da Riva et al.: Proteomic detection of a large
amount of SCGFa in the stroma of GISTs after imatinib therapy. Journal
of Translational Medicine 2011 9:158.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Da Riva et al. Journal of Translational Medicine 2011, 9:158
http://www.translational-medicine.com/content/9/1/158
Page 13 of 13